NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals’ Post

For decades, the Danish government has encouraged and supported public-private life science research funding that applies resources to projects across the entirety of the pharmaceutical development pipeline. Through this strategy, they've emphasized projects that create a real-world impact, which experts in Nature Portfolio credit for the country's outsized R&D output. Like Denmark, our industry must make our investments more equitable across the R&D pipeline to ensure the best therapies receive the funds they need to come to fruition. AI's ability to find patterns in existing data could be an efficient way to see where research investments are needed. https://lnkd.in/e4uMkP-2

Exciting news! Join me, Nitin, for a session on "Unleashing the Potential of Algorithm-Based Models in the Development of Directly Compressible Dosage Forms”. I will be discussing the use of ZoomLab(TM), an algorithm-based model that expedites formulation development by selecting drug delivery strategies based on API properties. Don't miss out on this insightful discussion!

It’s no surprise that pharmaceutical companies sponsor the majority of clinical trials. However, it's important to note that clinical trials sponsored by academic institutions, government organizations, and nonprofit organizations also make substantial contributions to medical research. 💪 These trials often focus on specific disease areas or unmet medical needs, and their sponsorship is driven by scientific curiosity, public health objectives, or philanthropic initiatives. At Yonalink, we recognize that there are many potential lifesaving therapeutics that don’t make it past the ideation phase due to financial challenges. That’s why we’re proud to offer our robust EDC for free for all investigator-initiated studies. 🎁 Are you planning an investigator-initiated study? We’re here for you – let’s discuss how we can help. #clinicalresearch #investigators #savemoney

I am pleased to announce that my paper has been published (as a co-author), and I am grateful for this achievement. I would like to express my gratitude to Allah for this success. The Laboratory of Biopharmaceutical and Bioinformatics has been thriving in the research sector, and I am proud to be a part of it. I would like to give special thanks to my teacher, Prof. Dr. Md. Nazmul Hasan, who has been devoted to research and has played a crucial role in my success. Paper Link: https://lnkd.in/gxMPGThJ #publication #biotechnology #diabetes #pharmaceuticals #research

🔬 Excited to share my recent achievement in the field of molecular docking! 🚀  I'm thrilled to announce that I have successfully completed the Molecular Docking Certification Program offered by Biotechnika. 🎓 Throughout the program, I delved into the principles and techniques of molecular docking, a crucial step in understanding the interactions between ligands and biomolecular targets. By applying cutting-edge software and algorithms, I learned to predict and analyze the binding affinities between small molecules and proteins, paving the way for the development of potential therapeutic agents.💡  The Biotechnika team's guidance and expertise were invaluable in honing my skills and understanding of this complex process. I was exposed to real-world case studies. This certification is not just a recognition of my efforts but also a testament to the incredible opportunities that lie ahead in the realm of biotechnology and pharmaceutical research. 🌟  I am now even more determined to contribute to the advancement of drug discovery and the development of life-changing therapies. As I move forward in my career, I eagerly look forward to collaborating with experts in the industry, utilizing the knowledge gained from this program to make a positive impact on human health. 🤝  #MolecularDocking #DrugDiscovery #Biotechnology #Certification #ComputationalBiology #Biotechnika #LinkedInLearning #LifeSciences #PharmaceuticalResearch #ResearchAndDevelopment

Day 3 at the Biotechnology Innovation Organization's annual conference! Yesterday our British Columbia Showcase put a spotlight on what makes our sector stand out and why we are making national news. Watch our sector snapshot video for some of the highlights. - We are home to Canada's largest life sciences companies STEMCELL Technologies StarFish Medical Xenon Pharmaceuticals Inc., to list a few. - Our sector has experienced double digit growth in recent years. - Biotech has attracted >US $13B in private investment over the past decade. - 20% of all Canadian spin-outs are from UBC. - The BC government invests heavily and identifies life sciences as a priority sector. - We are building infrastructure and developing talent to support our growth including in biomanufacturing and clinical trials. - Research innovation is a driving force with technologies developed and commercialized here. For example, we are home to lipid nanoparticle (LNP) technology that was a key constituent of early vaccines against COVID-19, and has multiple therapeutic applications. Thanks to support from Pacific Economic Development Canada | Développement économique Canada pour le Pacifique and the BC Provincial Government for helping us to profile BC at #BIO2024 and to biofilm MEDIA for the great work on this video. Wendy Hurlburt Ryan Butt

🌟 Exciting News for Glycoscientists! 🌟 We are thrilled to announce that we have 1 kg of UDP-GalNAz (Uridine diphosphate N-acetylgalactosamine azide) in stock and ready for your research needs! UDP-GalNAz is essential for: 🔬 Glycan labeling and visualization 🔬 Studying glycosylation processes 🔬 Advancing drug development 🔬 Discovering glycan biomarkers Whether you're conducting cutting-edge research or developing new therapeutics, our high-quality UDP-GalNAz can help accelerate your projects. Visit our website to order or contact us for more information. #Glycoscience #Research #UDPGalNAz #Biotechnology #Innovation #Glycoengineering #ADC

🌍 Bio & ASCO are just around the corner! 📢 They are some of the largest and most influential global events in the biotechnology industry. These conferences bring together a wide array of professionals from the biotech, pharmaceutical, and related sectors. 👨🔬 These conferences will feature over 100 educational sessions, 250 spoken presentations, 16 clinical science symposia, 24 abstract sessions, and more than 2,000 poster presentations. 🧬 As a head-hunter in the life sciences industry, these conferences are a prime venue and perfect opportunity to connect companies with prospective candidates. I can schedule informal meetings to discuss market trends and hiring strategies, explore a diverse talent pool, and identify top candidates who can drive innovation and growth in your organization. 🙋♂️ Are you attending one of the conferences this year? #ASCO2024 #BIO #Conferences #Networking #Biotech #Oncology

CQDM. We share. Are you looking for wet-lab space to help your venture grow? SBME Innovates, hosted by the University of British Columbia’s School of Biomedical Engineering, invites you to become part of a dynamic ecosystem of scientists, entrepreneurs, and innovators. Their mission is to catalyze innovation and collaboration, providing you with vital wet lab space and cutting-edge equipment to allow your venture to flourish. More information here: https://lnkd.in/gNX_HxrV #lifesciences #biotechnology #drugdevelopment #innovation #funding #projects #medical #research #intelligenceartificielle #artificialintelligence #pharmaceutique #pharmaceutical #biopharma #biopharmaceutical #rna #rnatherapeutics #arn #faciliterinnovationbiopharma #financement #cancer #innovative #ecosystem #congratulations School of Biomedical Engineering at UBC Sarah Fernando, PhD Danielle Walker The University of British Columbia ScopeSys Faculty of Medicine at the University of British Columbia Life Sciences BC UBC Engineering

🌟 Exciting News from Nano4Rare! 🌟 🌍 We are thrilled to announce the Nano4Rare EIC Transition project started on 1st November 2023 and led by the INSTITUT DE CIÈNCIA DE MATERIALS DE BARCELONA (ICMAB-CSIC). 🌐 About Nano4Rare: Nano4Rare is a European project financed by the European Innovation Council and SMEs Executive Agency (EISMEA). It has a singular focus: to bring a new #nanopharmaceutical product for the treatment of Fabry disease (named as nanoGLA) to First-in Human clinical trials. #NanoGLA is patent protected and was designated as Orphan Medicinal Product by the European Medicines Agency in 2021, two important milestones with high implications for the translation of the new therapeutic product from bench to bedside. Nano4Rare project is expected to mature the development of this innovative nanopharmaceutical product by completing the GLP preclinical phase and regulatory approval. To achieve this objective, we will account with the collaboration of NANOMOL TECHNOLOGIES, LeanBioPro, and MyBiotech GmbH, which are partners of its linked project 953110 PHOENIX OITB that will cover the Chemistry, Manufacturing, and Controls (CMC) development. Additionally, in the frame of Nano4Rare, an appropriate business strategy will be implemented to ensure the financing of further clinical trials and the arrival to the market. 🤝 Connect with Us: Follow Nano4Rare on LinkedIn for regular updates, insights, and opportunities to be part of this ground-breaking initiative. Together, we can make a difference! #Nano4Rare #RareDiseases #Innovation #Healthcare #ClinicalTrials #ICMAB #CSIC INSTITUT DE CIÈNCIA DE MATERIALS DE BARCELONA (ICMAB-CSIC) CSIC CSIC Innovación Centro de Investigación Biomédica en Red CIBER NANBIOSIS – ICTS